We are in Berlin for #ESMO25
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to you
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to you
October 17, 2025 at 9:46 AM
We are in Berlin for #ESMO25
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to you
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials. From the podium to you
COLLEAGUES, Reminder that the OncoAlert Newsletter will be coming Every day During #ESMO25! 🇩🇪 REGISTER HERE👉 buff.ly/RkOToac
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
Simple. Direct.
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
Simple. Direct.
October 17, 2025 at 1:30 PM
COLLEAGUES, Reminder that the OncoAlert Newsletter will be coming Every day During #ESMO25! 🇩🇪 REGISTER HERE👉 buff.ly/RkOToac
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
Simple. Direct.
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
Simple. Direct.
Welcome to #ESMO25 : The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 and Dr. Gil Morgan have selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
October 17, 2025 at 9:15 AM
Welcome to #ESMO25 : The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 and Dr. Gil Morgan have selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
September 30, 2025 at 11:42 AM
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
The OncoAlert🚨 Network along with our partners at
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
January 10, 2025 at 6:23 PM
The OncoAlert🚨 Network along with our partners at
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
want to see a shining example of #advocacy, for others, in honor of his mom after her #glioblastoma dx, and then for himself when he was diagnosed with #Castelman syndrome? Look no farther than @DavidFajgenbaum #ASCO20 @OncoAlert
November 18, 2024 at 8:26 AM
want to see a shining example of #advocacy, for others, in honor of his mom after her #glioblastoma dx, and then for himself when he was diagnosed with #Castelman syndrome? Look no farther than @DavidFajgenbaum #ASCO20 @OncoAlert
The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/xgIw0BISCpo
@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social
Covering May 15-22, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/xgIw0BISCpo
@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social
The OncoAlert Oncology Round Up May 15-22, 2025 Top Oncology Breakthroughs in less than 5 Min!
YouTube video by OncoAlert 360
youtu.be
May 22, 2025 at 10:03 AM
The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/xgIw0BISCpo
@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social
Covering May 15-22, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/xgIw0BISCpo
@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social
✨ #ASCO25 ✨
🚨BREAKING: Phase 3 CASSANDRA trial suggests preoperative PAXG may outperform mFOLFIRINOX in resectable PDAC
📈 PAXG showed 31% 3-year event-free survival vs 13% with mFOLFIRINOX (HR 0.64; P=.003)
🔗 Read more: bit.ly/ONCOnews1J-6
#OncoAlert #OncEd #ONCOnews #PancreaticCancer
🚨BREAKING: Phase 3 CASSANDRA trial suggests preoperative PAXG may outperform mFOLFIRINOX in resectable PDAC
📈 PAXG showed 31% 3-year event-free survival vs 13% with mFOLFIRINOX (HR 0.64; P=.003)
🔗 Read more: bit.ly/ONCOnews1J-6
#OncoAlert #OncEd #ONCOnews #PancreaticCancer
June 1, 2025 at 12:16 PM
✨ #ASCO25 ✨
🚨BREAKING: Phase 3 CASSANDRA trial suggests preoperative PAXG may outperform mFOLFIRINOX in resectable PDAC
📈 PAXG showed 31% 3-year event-free survival vs 13% with mFOLFIRINOX (HR 0.64; P=.003)
🔗 Read more: bit.ly/ONCOnews1J-6
#OncoAlert #OncEd #ONCOnews #PancreaticCancer
🚨BREAKING: Phase 3 CASSANDRA trial suggests preoperative PAXG may outperform mFOLFIRINOX in resectable PDAC
📈 PAXG showed 31% 3-year event-free survival vs 13% with mFOLFIRINOX (HR 0.64; P=.003)
🔗 Read more: bit.ly/ONCOnews1J-6
#OncoAlert #OncEd #ONCOnews #PancreaticCancer
The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
OncoAlert Weekly Round Up🚨 Aug 29-Sept 4 Covering ASTER70, CodeBreak300 IMmotion010 and more
YouTube video by OncoAlert 360
youtu.be
September 5, 2025 at 12:05 PM
The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
🔗 Read more: bit.ly/ONCOnews16O-1
#ONCOnews #OncoAlert #OncEd #BloodCancer #Oncology #Hematology #ClinicalTrials
#ONCOnews #OncoAlert #OncEd #BloodCancer #Oncology #Hematology #ClinicalTrials
October 16, 2025 at 12:30 PM
November 10, 2025 at 12:30 PM
Dear Colleagues
A warm invitation to JOIN US at #APCCCDiagnostics25
A HYBRID Meeting (In Person & Live) in Lugano Switzerland February 27-28, 2025
REGISTER: https://buff.ly/4eSVBsa
Enjoy Early Bird Registration, NOW OPEN
ONLINE REGISTRATION FOR LMIC's FREE‼️
OncoAlert 🚨Will be Livewith Coverage
A warm invitation to JOIN US at #APCCCDiagnostics25
A HYBRID Meeting (In Person & Live) in Lugano Switzerland February 27-28, 2025
REGISTER: https://buff.ly/4eSVBsa
Enjoy Early Bird Registration, NOW OPEN
ONLINE REGISTRATION FOR LMIC's FREE‼️
OncoAlert 🚨Will be Livewith Coverage
November 30, 2024 at 3:33 PM
Dear Colleagues
A warm invitation to JOIN US at #APCCCDiagnostics25
A HYBRID Meeting (In Person & Live) in Lugano Switzerland February 27-28, 2025
REGISTER: https://buff.ly/4eSVBsa
Enjoy Early Bird Registration, NOW OPEN
ONLINE REGISTRATION FOR LMIC's FREE‼️
OncoAlert 🚨Will be Livewith Coverage
A warm invitation to JOIN US at #APCCCDiagnostics25
A HYBRID Meeting (In Person & Live) in Lugano Switzerland February 27-28, 2025
REGISTER: https://buff.ly/4eSVBsa
Enjoy Early Bird Registration, NOW OPEN
ONLINE REGISTRATION FOR LMIC's FREE‼️
OncoAlert 🚨Will be Livewith Coverage
Planning Automation for Treatment Techniques Comparison and Robustness Analysis: Tangential IMRT and VMAT for Whole Breast Irradiation
#BreastCancer #medphys #radonc #OncoAlert
@oncoalert.bsky.social
Free 50-day link:
www.advancesradonc.org/article/S245...
#BreastCancer #medphys #radonc #OncoAlert
@oncoalert.bsky.social
Free 50-day link:
www.advancesradonc.org/article/S245...
Planning Automation for Treatment Techniques Comparison and Robustness Analysis: Tangential Intensity Modulated Radiation Therapy and Volumetric Modulated Arc Therapy for Whole Breast Irradiation
This study evaluates the use of the mCycle automated planning system integrated into
the Monaco Treatment Planning System for step-and-shoot intensity modulated radiation
therapy (IMRT) and volumetric...
www.advancesradonc.org
February 27, 2025 at 6:30 AM
Planning Automation for Treatment Techniques Comparison and Robustness Analysis: Tangential IMRT and VMAT for Whole Breast Irradiation
#BreastCancer #medphys #radonc #OncoAlert
@oncoalert.bsky.social
Free 50-day link:
www.advancesradonc.org/article/S245...
#BreastCancer #medphys #radonc #OncoAlert
@oncoalert.bsky.social
Free 50-day link:
www.advancesradonc.org/article/S245...
Thank you Dr Bardia for recognizing that patient centered dosing - and involvement of those of us living with #MBC - is key in providing the best care #SABCS19 #oncoalert #bcsm
November 18, 2024 at 11:56 AM
Thank you Dr Bardia for recognizing that patient centered dosing - and involvement of those of us living with #MBC - is key in providing the best care #SABCS19 #oncoalert #bcsm
✨#ASCO25✨
🚨BREAKING: 5-Year Results from IMpower010 Trial!
Atezolizumab after chemo shows sustained survival benefit in resected Stage IB–IIIA NSCLC
✅ Long-term outcomes support continued benefit of adjuvant immunotherapy
🔗 Read now: bit.ly/ONCOnews31M-3
#OncoAlert #OncEd #LungCancer #ONCOnews
🚨BREAKING: 5-Year Results from IMpower010 Trial!
Atezolizumab after chemo shows sustained survival benefit in resected Stage IB–IIIA NSCLC
✅ Long-term outcomes support continued benefit of adjuvant immunotherapy
🔗 Read now: bit.ly/ONCOnews31M-3
#OncoAlert #OncEd #LungCancer #ONCOnews
May 31, 2025 at 6:20 AM
✨#ASCO25✨
🚨BREAKING: 5-Year Results from IMpower010 Trial!
Atezolizumab after chemo shows sustained survival benefit in resected Stage IB–IIIA NSCLC
✅ Long-term outcomes support continued benefit of adjuvant immunotherapy
🔗 Read now: bit.ly/ONCOnews31M-3
#OncoAlert #OncEd #LungCancer #ONCOnews
🚨BREAKING: 5-Year Results from IMpower010 Trial!
Atezolizumab after chemo shows sustained survival benefit in resected Stage IB–IIIA NSCLC
✅ Long-term outcomes support continued benefit of adjuvant immunotherapy
🔗 Read now: bit.ly/ONCOnews31M-3
#OncoAlert #OncEd #LungCancer #ONCOnews
💫#ONCOnews💫
🚨 BREAKING: EU approves Calquence + chemoimmunotherapy as the first BTK inhibitor for frontline mantle cell lymphoma! 🧬
📈 Backed by ECHO Phase III trial: 16+ months PFS gain vs. chemoimmunotherapy alone.
🔗 Read more: bit.ly/ONCOnews07M-1
#OncoAlert #OncEd #Lymphoma #CancerResearch
🚨 BREAKING: EU approves Calquence + chemoimmunotherapy as the first BTK inhibitor for frontline mantle cell lymphoma! 🧬
📈 Backed by ECHO Phase III trial: 16+ months PFS gain vs. chemoimmunotherapy alone.
🔗 Read more: bit.ly/ONCOnews07M-1
#OncoAlert #OncEd #Lymphoma #CancerResearch
May 7, 2025 at 6:48 AM
💫#ONCOnews💫
🚨 BREAKING: EU approves Calquence + chemoimmunotherapy as the first BTK inhibitor for frontline mantle cell lymphoma! 🧬
📈 Backed by ECHO Phase III trial: 16+ months PFS gain vs. chemoimmunotherapy alone.
🔗 Read more: bit.ly/ONCOnews07M-1
#OncoAlert #OncEd #Lymphoma #CancerResearch
🚨 BREAKING: EU approves Calquence + chemoimmunotherapy as the first BTK inhibitor for frontline mantle cell lymphoma! 🧬
📈 Backed by ECHO Phase III trial: 16+ months PFS gain vs. chemoimmunotherapy alone.
🔗 Read more: bit.ly/ONCOnews07M-1
#OncoAlert #OncEd #Lymphoma #CancerResearch
Reminder that the OncoAlert Newsletter will be coming Every day During #ESMO25! 🇩🇪
REGISTER HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
REGISTER HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
October 13, 2025 at 4:40 PM
Reminder that the OncoAlert Newsletter will be coming Every day During #ESMO25! 🇩🇪
REGISTER HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
REGISTER HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
Whether you’re attending in person or following from afar, don’t miss the OncoAlert Newsletter — delivering our TOP trial picks from the congress each day.
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
October 30, 2025 at 10:00 AM
The OncoAlert TOP STACK: DESTINY Breast 09
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
T-DXd plus pertuzumab significantly improves outcomes versus THP across all subgroups of HER2-positive advanced or metastatic #BreastCancer , with a consistent safety profile.
🔗 Read more: bit.ly/ONCOnews30O-2
#ONCOnews #OncoAlert #OncEd #CancerNews #CancerResearch #LiverCancer
#ONCOnews #OncoAlert #OncEd #CancerNews #CancerResearch #LiverCancer
October 30, 2025 at 12:30 PM
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
October 31, 2025 at 10:00 AM
The OncoAlert 🚨 TOP STACK: IMvigor011
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
Appendiceal cancer is NOT the same as colon cancer: Implications for #chemotherapy. Join us for this FREE educational webinar featuring @jpshen_md, an Assistant Professor at @MDAndersonNews. Open to all! #oncoalert #appendixcancer #CancerResearch...
November 23, 2024 at 12:21 AM
Appendiceal cancer is NOT the same as colon cancer: Implications for #chemotherapy. Join us for this FREE educational webinar featuring @jpshen_md, an Assistant Professor at @MDAndersonNews. Open to all! #oncoalert #appendixcancer #CancerResearch...
@UNM @UnmHealth @UNMSOM_GI @OncoAlert
November 22, 2024 at 11:38 PM
@UNM @UnmHealth @UNMSOM_GI @OncoAlert
“the impossible can be changed when patients have a voice” Shawn Johnson @harvardmed student speaking at @tigerlilycares #listenupMBC event #SABCS19 #oncoalert #bcsm
November 18, 2024 at 12:29 PM
“the impossible can be changed when patients have a voice” Shawn Johnson @harvardmed student speaking at @tigerlilycares #listenupMBC event #SABCS19 #oncoalert #bcsm
Applause for @tmprowell asking the “tough conversations” panel about how physicians can self advocate to change the system so they can do what they wanted to do - take care of people. #SABCS19 #oncoalert #bcsm
November 18, 2024 at 11:09 AM
Applause for @tmprowell asking the “tough conversations” panel about how physicians can self advocate to change the system so they can do what they wanted to do - take care of people. #SABCS19 #oncoalert #bcsm
3/3 (I can’t count!) #TNBC #MBC sacituzumab, this time with govitecan (NOT same ADC as DS8201), targeting Trop2 which is expressed in TNBC. A third of people responded.#SABCS19 #oncoalert #bcsm
November 18, 2024 at 10:47 AM
3/3 (I can’t count!) #TNBC #MBC sacituzumab, this time with govitecan (NOT same ADC as DS8201), targeting Trop2 which is expressed in TNBC. A third of people responded.#SABCS19 #oncoalert #bcsm